This application requests renewal for years 24-28 of the NCI Cancer Center Support Grant (CCSG) for the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit at Wayne State University. The Cancer Center, which is managed by the Karmanos Cancer Institute, has re-established a strong trajectory of research growth with a significant re-organization of its administrative services and organization, new leadership and ant increase in peer-reviewed funding.The programs of the Cancer Center reflect the cancer needs of the greater Metropolitan Detroit area. This is an industrialized, urban and ethnically diverse community with a disproportionate number of medically disadvantaged, low socio-economic citizens. This Cancer Center has a long-standing and extensive commitment to both research and clinical services that address the prevention, earlier detection and treatment of cancer, particularly of African American and Arab American populations which experience disproportionate mortality from breast, prostate and aero-digestive cancers. Our grant requests support for five research programs, ten core facilities, five senior leaders, five staff investigators, developmental funds, and related administrative support. The Cancer Center's established research programs are Breast Cancer; Developmental Therapeutics; Molecular Biology and Human Genetics; Population Studies and Prevention, and Proteases and Cancer. CCSG support is also requested for Cores in Bioinformatics, Biostatistics, Cancer Center Informatics, Clinical Trials Office, Cell Resources, Genomics, Human Tissue and Pathology, Confocal Imaging, Flow Cytometry and Pharmacology. Our Programs are organized to integrate basic, translational, and clinical research with population research-based, cancer control activities. The Cancer Center will continue to foster intra- and inter-disciplinary interactions and collaborations, and to utilize CCSG developmental funds to recruit new investigators and to develop translational research programs that have a high potential for peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-25S1
Application #
7292136
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-08-08
Project End
2009-11-30
Budget Start
2006-03-03
Budget End
2006-11-30
Support Year
25
Fiscal Year
2006
Total Cost
$228,404
Indirect Cost
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58

Showing the most recent 10 out of 826 publications